Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)

Table 3 AIT-like desensitization protocol for idursulfase

step	inj # 1			inj # 2			inj # 3						*total (mg)
	conc. (mg/ml)	vol. (ml)	dose (mg)	conc. (mg/ml)	vol. (ml)	dose (mg)	conc. (mg/ ml)	vol. (ml)	dose (mg)	conc. (mg/ml)	vol. (ml)	dose (mg)
1	0.02	0.1	0.002	0.02	0.1	0.002	0.02	0.2	0.004				0.008
2	0.02	0.3	0.006	0.02	0.3	0.006	0.02	0.3	0.006				0.018
3	0.2	0.15	0.03	0.2	0.15	0.03	0.2	0.3	0.06				0.12
4	0.2	0.3	0.06	0.2	0.3	0.06	0.2	0.6	0.12				0.24
5	2	0.15	0.3	2	0.15	0.3	2	0.15	0.3	2	0.15	0.3	1.2
6	2	0.25	0.5	2	0.25	0.5	2	0.25	0.5	2	0.25	0.5	2
7	2	0.5	1	2	0.5	1	2	0.5	1	2	0.5	1	4
8	2	0.5	1	2	0.5	1	2	0.5	1	2	0.5	1	4
9	2	0.5	1	2	0.5	1	2	0.5	1	2	0.5	1	4
10	2	0.5	1	2	0.5	1	2	0.5	1	2	0.5	1	4
11	2	0.5	1	2	0.5	1	2	0.5	1	2	0.5	1	4

Total dose administered over approx. 24 days: 23.59 mg. Inj #1 – Inj #4: at each step/session 3 or 4 subcutaneous injections were given, 20’apart from each other. *Total dose administered at each step (consisting of 3–4 subcutaneous injections)

ISSN: 1750-1172